- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06902480
Mejeri kolinbiotillgänglighet
Bedömning av kolinbiotillgänglighet och metabolism från en ny mejeriingrediens för kvinnor efter menopausen
The goal of this clinical trial is to find out if dairy is a good source of choline compared to eggs. The main questions it aims to answer are:
- How the body uses choline; and,
- What effect WPPC has on choline metabolism.
Researchers will compare Whey Protein Phospholipid Concentrate (WPPC) to whole egg powder to see if WPPC is as effective as eggs.
Participants will drink a chocolate-flavored smoothie mixed with either WPPC or whole egg powder.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study is intended to evaluate the bioavailability and metabolism of choline in WPPC compared to the most commonly -used food for bioavailable choline, whole egg. The intent of the evaluation is to improve the knowledge of how WPPC contributes to the nutritional needs and health of postmenopausal women.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Kevin Shih
- Telefonnummer: 919-338-9453
- E-post: sshih22@wisc.edu
Studieorter
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53705
- Rekrytering
- University of Wisconsin - Madison
-
Huvudutredare:
- Bradley Bolling, PhD
-
Kontakt:
- Kevin Shih
- E-post: sshih22@wisc.edu
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Ages between 51 and 70
- Is currently post-menopausal (Post-menopausal is a term used to describe the time in a woman's life after she has gone through menopause. This usually happens between the ages of 45 and 55. Menopause is when a woman's menstrual periods stop permanently (at least 12 months))
- Not allergic to the intervention foods and allergens that are related to the production of intervention foods (e.g. dairy products, egg, fish, peanut, shellfish, soy, tree nuts, wheat, crustaceans, gluten, mollusks, mustard, sesame seeds.)
- Had stable body weight (± 5%) for the past 6 months
- Free from cancer
- Did not have weight loss surgery, colon surgery
- Do not have chronic kidney diseases
- Do not have malabsorption towards fat and dairy products
- Willing to complete health surveys
- Willing to complete two 4-day food diaries
- Willing to consume the intervention smoothies
- Willing to provide blood, urine, fecal samples at baseline and after 10 days of intervention
Exclusion Criteria:
- On weight loss/weight gain diets
- Diagnosed with fat malabsorption
- Undergoing weight loss surgery
- Diagnosed with chronic kidney diseases
- Allergic to the intervention foods and allergens that are related to the production of intervention foods (e.g. dairy products, egg, chocolate, fish, peanut, shellfish, soy, tree nuts, wheat, crustaceans, gluten, mollusks, mustard, sesame seeds, banana, strawberry, raspberry, blackberry, blueberry.)
- Regularly using antibiotics or probiotics or prebiotics
- Regularly using weight-loss drugs (GLP-1, Orlistat, Cetilistat, etc.)
- Regularly using laxatives
- Unable to avoid strenuous exercise during the study (>4 h vigorous exercise per day)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Övrig
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Whey Protein Phospholipid Concentrate (WPPC)
Participants will drink a chocolate-flavored smoothie with WPPC added |
A chocolate-flavored smoothie with WPPC added |
|
Experimentell: Pasteurized whole egg powder
Participants will drink a chocolate-flavored smoothie with egg powder added |
A chocolate-flavored smoothie with whole egg powder added |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in circulating choline
Tidsram: Baseline to 10 days
|
Circulating choline will be measured by UHPLC-HRMS/MS |
Baseline to 10 days
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in co-factors in circulating choline
Tidsram: Baseline to 10 days
|
Co-factors in the circulation will be measured by ultrahigh performance liquid chromatography coupled with high resolution tandem mass spectrometry (UHPLC-HRMS/MS). |
Baseline to 10 days
|
|
Change in high-sensitivity C-reactive protein (hs-CRP)
Tidsram: Baseline to 10 days
|
Safety biomarker Hs-CRP will be measured using immunoturbidimetry. |
Baseline to 10 days
|
|
Change in circulating choline metabolites
Tidsram: Baseline to 10 days
|
Metabolites will be measured by UHPLC-HRMS/MS. |
Baseline to 10 days
|
|
Change in 8-hydroxydeoxyguanosine
Tidsram: Baseline to 10 days
|
The safety biomarker 8-hydroxydeoxyguanosine (8-OHDG) will be measured using enzyme-linked immunosorbent assay (ELISA). |
Baseline to 10 days
|
|
Change in aspartate transaminase
Tidsram: Baseline to 10 days
|
Aspartate transaminase (AST) will be measured using kinetic methods. |
Baseline to 10 days
|
|
Change in alanine transaminase (ALT)
Tidsram: Baseline to 10 days
|
Alanine transaminase will be measured using kinetic methods. |
Baseline to 10 days
|
|
Change in creatinine
Tidsram: Baseline to 10 days
|
Creatinine will be measured using kinetic methods |
Baseline to 10 days
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Bradley Bolling, PhD, University of Wisconsin, Madison
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- 2024-1661
- A074000 (Annan identifierare: UW Madison)
- CALS/FOOD SCIENCE (Annan identifierare: UW Madison)
- Protocol Version 4/24/2026 (Annan identifierare: UW Madison)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
The research team will share the individual participant data collected during the trial after deidentification. Deidentified data will be stored and shared with DryAd and in accordance with all applicable regulations.
Tidsram för IPD-delning
Anticipated data availability will be immediately following publication. No end date.
Kriterier för IPD Sharing Access
Data will be shared with DryAd. The data generated in this study will be housed in DryAd.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .